ストックスクリーナーアプリを入手
41.00
1.89%
-0.79
アフターアワーズ：
40.90
-0.10
-0.24%
Xenon Pharmaceuticals Inc (XENE) 最新ニュース
Why Xenon Pharmaceuticals Inc. stock remains undervalued2026 world cup usa national team third place match playmakers high defensive line expert forecast preview - Улправда
Why Xenon Pharmaceuticals stock is down today as JPM Healthcare Conference nears - ts2.tech
Xenon Pharmaceuticals (NASDAQ:XENE) Hits New 12-Month HighTime to Buy? - MarketBeat
Xenon to Showcase Neuroscience Pipeline at J.P. Morgan Healthcare Conference - TipRanks
Cantor Fitzgerald raises Xenon Pharmaceuticals stock price target to $55 By Investing.com - Investing.com UK
Xenon Pharmaceuticals Inc. to Present at 44th Annual J.P. Morgan Healthcare Conference in January 2026 - Quiver Quantitative
Xenon to Present at the 44th Annual J.P. Morgan Healthcare Conference - Bluefield Daily Telegraph
(XENE) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Xenon Pharmaceuticals (NASDAQ:XENE) CEO Ian Mortimer Sells 40,000 Shares - Defense World
Xenon Pharmaceuticals (NASDAQ:XENE) Shares Up 3.8% – Should You Buy? - Defense World
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Receives Consensus Recommendation of "Buy" from Brokerages - MarketBeat
Xenon Pharmaceuticals (NASDAQ:XENE) Trading 3.8% HigherHere's Why - MarketBeat
Analysts Conflicted on These Healthcare Names: Lifecore Biomedical (LFCR) and Xenon (XENE) - The Globe and Mail
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Novavax (NVAX), Xenon (XENE) and Biohaven Ltd. (BHVN) - The Globe and Mail
Commit To Purchase Xenon Pharmaceuticals At $32.50, Earn 25.8% Annualized Using Options - Nasdaq
Xenon announces new data on 48-month azetukalner OLE study data - MSN
Stifel reiterates Buy rating on Xenon Pharmaceuticals stock amid competitor setback - Investing.com Canada
Biohaven Misses The Mark In Depression Trial, Stock Falls - Sahm
Traders Purchase High Volume of Xenon Pharmaceuticals Put Options (NASDAQ:XENE) - MarketBeat
Why (XENE) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Can Xenon Pharmaceuticals Inc. stock deliver surprise earnings beatMarket Performance Summary & Stepwise Swing Trade Plans - bolumsonucanavari.com
Pullback Watch: How rising interest rates impact Xenon Pharmaceuticals Inc. stockMarket Sentiment Report & Growth Focused Stock Pick Reports - Улправда
Analysts Offer Insights on Healthcare Companies: Xenon (XENE) and 4D Molecular Therapeutics (FDMT) - The Globe and Mail
Returns Recap: Why Xenon Pharmaceuticals Inc. stock remains undervaluedJuly 2025 PostEarnings & Capital Efficient Trading Techniques - Улправда
Will Xenon Pharmaceuticals Inc. stock outperform tech sector in 20252025 Price Targets & Long Hold Capital Preservation Plans - Улправда
Can Xenon Pharmaceuticals Inc. stock resist sector downturns2025 Price Momentum & Precise Entry and Exit Recommendations - Улправда
Xenon Pharmaceuticals Inc (XENE)’s stock price in review: A technical analysis - uspostnews.com
Is Xenon Pharmaceuticals Inc. stock attractive for passive investorsPortfolio Update Report & AI Powered Buy and Sell Recommendations - Улправда
How rising interest rates impact Xenon Pharmaceuticals Inc. stockForecast Cut & High Conviction Buy Zone Alerts - Улправда
Xenon Pharmaceuticals: Derisked Pipeline Ahead Of Critical 2026 Phase 3 Readout (NASDAQ:XENE) - Seeking Alpha
Xenon Pharmaceuticals Inc. $XENE is Braidwell LP's 7th Largest Position - MarketBeat
Xenon Pharmaceuticals Inc. (XENE) Discusses Latest Phase III Updates for Azetukalner in Epilepsy and Commercial Launch PreparationSlideshow (NASDAQ:XENE) 2025-12-12 - Seeking Alpha
Xenon Pharmaceuticals (NASDAQ:XENE) Given New $48.00 Price Target at Wells Fargo & Company - Defense World
Wells Fargo Maintains Xenon Pharmaceuticals (XENE) Overweight Recommendation - Nasdaq
XENE Stock Update: Wells Fargo Raises Price Target to $48 | XENE - GuruFocus
Russell Investments Group Ltd. Decreases Holdings in Xenon Pharmaceuticals Inc. $XENE - MarketBeat
Xenon Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:XENE) - MarketBeat
Xenon projects top line X-TOLE2 data in early 2026 as enrollment surpasses target, expanding late-stage pipeline - MSN
Transcript : Xenon Pharmaceuticals Inc.Special Call - marketscreener.com
Ian Mortimer Sells 10,830 Shares of Xenon Pharmaceuticals (NASDAQ:XENE) Stock - MarketBeat
Insider Selling: Xenon Pharmaceuticals (NASDAQ:XENE) CEO Sells 14,375 Shares of Stock - MarketBeat
Ian Mortimer, Xenon Pharma CEO, sells $1.14m in shares By Investing.com - Investing.com South Africa
Ian Mortimer, Xenon Pharma CEO, sells $1.14m in shares - Investing.com
Xenon Pharmaceuticals President & CEO Ian Mortimer Sells Shares - TradingView — Track All Markets
Xenon Pharmaceuticals unveils promising long-term epilepsy treatment data - MSN
CEO Mortimer Files To Sell 10,830 Of Xenon Pharmaceuticals Inc [XENE] - TradingView — Track All Markets
Marshall Wace LLP Acquires 262,109 Shares of Xenon Pharmaceuticals Inc. $XENE - MarketBeat
Xenon Pharmaceuticals (NASDAQ:XENE) Sets New 1-Year High – Here’s What Happened - Defense World
Is Xenon Pharmaceuticals (XENE) Quietly Reframing Its Epilepsy Bet Through Equity Awards and New Data? - Yahoo Finance
Xenon Pharmaceuticals issues equity inducement grants to new employees - MSN
New York State Common Retirement Fund Purchases 24,100 Shares of Xenon Pharmaceuticals Inc. $XENE - MarketBeat
Rhumbline Advisers Grows Stock Holdings in Xenon Pharmaceuticals Inc. $XENE - MarketBeat
2.52%
0.07%
大文字化:
|
ボリューム (24 時間):